ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0519

Prevalence of Diabetes, Hypertension, Anemia, and Hyperkalemia as Frequent Comorbidities in Patients with CKD Regardless of their KDIGO Staging

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Perez-Navarro, L. Monserrat, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Escorza Valdivia, Samantha, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
  • Benitez Renteria, Alberto Sigfrido, AstraZeneca, Ciudad de México, Ciudad de Mexico, Mexico
  • Valdez-Ortiz, Rafael, Hospital General de Mexico Dr Eduardo Liceaga, Ciudad de Mexico, Ciudad de Mexico, Mexico
Background

Chronic kidney disease (CKD) is a worldwide public health problem. Currently in Mexico, the prevalence of CKD is only an estimate, based primarily on records of advanced stages of the disease. It is necessary to identify comorbidities and thus establish strategies to delay its progression and reduce morbimortality associated with CKD.Objective: To know the prevalence of comorbidities associated with CKD at different stages in an outpatient population who attended a 3rd level hospital.

Methods

This is a cross-sectional retrolective study. Records of adult patients who attended an outpatient nephrology consultation in the period from February 2019 to February 2020 were included, with laboratory reports from 15 days prior to the inclusion date. Descriptive statistics were performed, with a 95% CI and a value of p≤0.05.

Results

1772 patient records were included. 51% (907) were women, the mean age was 42 ± 24.2 years. 12% were on renal replacement therapy, 11% hemodialysis and 1% peritoneal dialysis. 87% (1546) lacked family history of CKD; 11% (192) were smokers. Regarding body mass index, 2% (32) presented low weight, 37% (562) normal weight, 53% (804) overweight and 8% (122) obesity. Figure 1 shows the distribution by CKD stage and main comorbidities. The prevalence of proteinuria was 39% (693). 53% (826) had anemia. The prevalence of hyperkalemia (HK; K+≥5) was 29% (325). The prevalence of serum albumin <3.5 was 26%; 44% of the population had glucose> 100 mg/dl; 53% with triglyceride >150 mg/dl and 29% with total cholesterol ≥200 mg/dL.

Conclusion

A high prevalence of CKD comorbid risk factors such as diabetes, hypertension, anemia and HK were identified regardless of CKD staging, increasing in proportion in later stages.

Funding

  • Commercial Support